SCHEMBL22795333

SCHEMBL22795333

CCOC(=O)c1nnn(Cc2ccc(OC)cc2)c1Nc1ccc(C=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 3/20 0.45
RXFP1 Q9HBX9 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALOX15 P16050 1/20 0.45
CYP19A1 P11511 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
UCHL1 P09936 1/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
AKR1C3 P42330 2/20 0.41
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
PDE4B Q07343 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296878 0.93 MEN1 (0.51) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22815669 0.86 CYP19A1 (0.56) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22815720 0.86 TP53 (0.49) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22816474 0.85 MEN1 (0.46) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22816734 0.84 CYP19A1 (0.48) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22815534 0.84 TP53 (0.47) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22816573 0.84 MEN1 (0.49) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22816685 0.83 CYP19A1 (0.46) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22815949 0.83 AKR1C3 (0.47) MEN1KMT2APOLBRXFP1L3MBTL1
SCHEMBL22816547 0.83 CYP19A1 (0.47) MEN1KMT2APOLBRXFP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX MEN1 3426/4885KMT2A 3943/4885POLB 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.